What Submission Strategies Are Affected by the Updated Singapore HSA Medical Device Grouping Registration Guidance?

The updated Singapore HSA medical device grouping registration guidance affects submission strategies by requiring companies to reassess whether models, families, systems, procedure packs or IVD combinations in the same registration application meet the grouping conditions. Grouping can improve efficiency only when the products are sufficiently consistent in intended use, design features, risk classification, technical principles and labeling. If substantially different models are forced into the same group, the application may receive deficiency letters, require split submissions or face longer review timelines. For multi-model, multi-configuration and system-type products, the pre-submission grouping strategy directly affects cost, timeline and certificate coverage.

Article type: FAQ

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

Key Summary

After the Singapore HSA medical device grouping registration guidance update, companies should reassess whether models, families, systems, procedure packs or IVD combinations in the same registration application satisfy the grouping criteria. Grouping registration can improve efficiency, but only if the products are sufficiently consistent in intended use, design features, risk class, technical principles and labeling. If companies force substantially different models into one group, this may lead to deficiency responses, split submissions or extended review timelines. For multi-model, multi-configuration and system-type products, the grouping strategy before registration directly affects cost, timeline and certificate coverage.

Reference Basis

Official source: HSA

Source link: https://www.hsa.gov.sg/medical-devices/guidance-documents/

This article is prepared based on official public information and AIMEILI medical device international registration project experience. Specific pathways should still be determined according to product risk class, intended use and the latest requirements of the regulatory authority.

Who Should Read This

This content is suitable for medical device manufacturers, regulatory affairs professionals, overseas market leads and CRO teams preparing national registration and documentation projects. If a company already has China, EU, US or other market documentation but is unsure whether it can be reused in the target market, it should also read this and complete a gap assessment before project initiation.

Regulatory Assessment Logic

Companies should first confirm the product's regulatory status, risk class, intended use, applicable regulatory pathway and local responsible entity, and then determine the required depth of documentation. HSA-related requirements generally do not assess a single document in isolation; they also consider whether product claims, technical evidence, labels and instructions for use, quality system and post-market responsibilities are consistent.

Documentation Preparation Priorities

It is advisable to build the documentation package around product description, model specifications, risk management, performance verification, clinical or evaluation evidence, quality system, labels and instructions for use, authorization documents, UDI or traceability information, change management and post-market surveillance. For software, AI, IVD, sterile, active and medium- to high-risk products, specialized evidence should also be supplemented.

Company Action Steps

• First, establish a product and model list.
• Second, reclassify the products for the target market.
• Third, verify the coverage of existing certificates and test reports.
• Fourth, identify labeling, language, local representative and post-market obligations.
• Fifth, create a gap list and supplementary documentation plan.
• Sixth, arrange translation, signing, submission and responses to review questions.

Common Errors

Common errors include directly translating domestic documents, ignoring the local responsible entity, over-relying on existing CE or FDA documentation, unclear product model coverage, label claims that exceed the evidence scope, and missing post-market surveillance and change processes. Regulators are mainly concerned with whether the evidence chain is closed, not with the number of documents.

AIMEILI Professional Recommendations

AIMEILI recommends including this issue in the registration project initiation assessment rather than supplementing documents only before submission. A more robust approach is to first complete pathway determination and documentation gap assessment, and then manage the target country, product classification, documentation reuse, additional testing, local representative and post-market maintenance in one project plan.

Internal Checklist

• Are product classification, intended use and model scope clear?
• Do existing certificates, test reports and technical files cover the application scope?
• Are the responsibilities of the local representative, Sponsor or registration holder clear?
• Have labels and instructions for use, UDI, language and post-market maintenance been planned?
• Has a documentation gap list and supplementary testing plan been formed?
• Have official sources and applicability boundary statements been retained?

Continue Reading

Previous: After Australia TGA UDI implementation, how should Class IIb and Class III products prepare?

Next: After Japan PMDA updates the SaMD page, what should software medical device registration focus on?

Recommended Reading

• What should companies prepare after the Canada Health Canada medical device regulatory registration process update?
• What documents are required before Singapore HSA medical device registration?
• What compliance obligations should be confirmed before Australia TGA medical device registration?
• What should companies prepare before Australia TGA medical device registration?
• Can CE documentation be reused for Singapore HSA medical device registration?
• What core documents are required for UAE MOHAP medical device registration?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Prioritize official regulatory authorities, international organizations, standards organizations and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the official requirements of target country regulators, test conclusions or legal advice.